BACKGROUND Early diagnosis of colorectal cancer(CRC)is of great significance to improve the survival rate and quality of life of patients,but early diagnosis of CRC requires more sensitive techniques.Peripheral blood ...BACKGROUND Early diagnosis of colorectal cancer(CRC)is of great significance to improve the survival rate and quality of life of patients,but early diagnosis of CRC requires more sensitive techniques.Peripheral blood UL16-binding protein 2(ULBP2)and human fibrinogen degradation products(DR-70)are the main indicators for the diagnosis of malignant tumors.AIM To assess ULBP2 and DR-70 potential for the early diagnosis and prognostic evaluation of CRC to provide a reference.METHODS This study involved 60 patients with early-stage CRC(CRC group),50 patients with benign colorectal tumors(benign group),and 50 healthy patients(control group)enrolled at the Affiliated Hospital of Jiangnan University and Jiangsu Province Official Hospital between January,2020 and January,2022.ULBP2 and DR-70 levels in the blood were determined and differences among the three groups and early diagnostic values for CRC were determined.Patients with CRC were divided into the good prognosis and poor prognosis groups,and ULBP2 and DR-70 levels in the blood and diagnostic values were compared.RESULTS ULBP2 and DR-70 serum levels were significantly higher in the CRC group than in the control and benign groups(P<0.05);however,no significant differences were observed between the benign and control groups(P>0.05).Among the 60 patients with CRC followed up for two years,two died(3.33%)and 15 exhibited tumor metastasis,progression,or recurrence(25.00%).ULBP2 and DR-70 serum levels were significantly higher in the poor prognosis group than in the good prognosis group(P<0.05).A receiver operating characteristic curve was plotted.Area under the curve,sensitivity,and specificity of serum ULBP2 with DR-70 for the early diagnosis of CRC were higher than those of the single serum indices(P<0.05)in both the good and poor prognosis groups.CONCLUSION ULBP2 and DR-70 serum levels were significantly high in patients with early-stage CRC.They improved the diagnostic rate of early-stage CRC and predicted patient prognosis,thereby showing clinical application potential.展开更多
Background and question: Malignant cells characteristically possess high levels of proteases (e.g. plasminogen activator, cathepsin etc.), which should induce fibrinolysis. The DR- 70(tm) immunoassay quantifies the am...Background and question: Malignant cells characteristically possess high levels of proteases (e.g. plasminogen activator, cathepsin etc.), which should induce fibrinolysis. The DR- 70(tm) immunoassay quantifies the amount of fibrin degradation products (FDP) in the body. This test system has successfully been used for the detection of a number of cancers including lung, stomach, breast, rectum, liver, colon and uterus cancer. In this paper we tested the diagnostic validity of DR- 70(tm) relative to CA- 125 as a tumor marker for the detection of ovarian carcinoma. Methods: We have simultaneously investigated the serum activities of DR- 70(tm)and CA- 125 from 61 preoperative patients with histologically confirmed ovarian carcinoma. One hundred healthy blood donors served as control group. We measured the FDP utilizing the DR- 70(tm) ELISA as per test instructions of its manufacturer AMDL (Tustin, CA, USA). Results: Low levels of FDP measured by DR- 70(tm) have been detected in the serum of 100 apparently healthy persons (mean ± S.D., 0.41 ± 0.19 μ g/ml). Among the 61 ovarian carcinoma patients, DR- 70(tm) mean value (± S.D.) was 7.0 ± 10.5 μ g/ml in a range of 0.6 to 58.5 μ g/ml. The cut- off level for DR- 70(tm) was set at > 1.2 μ g/ml. The specificity was 100% , whereas the sensitivity was at 83.6% . Relative to CA- 125 a cut- off level of > 65 U/ml was applied. The comparable sensitivity of DR- 70(tm) was higher by 13.1 % . Conclusions: Malignant cells with high levels of proteases are significant contributors to fibrinolysis. The DR- 70(tm) immunoassay has been designed to measure the level of FDP in the serum. DR- 70(tm) represents a tumor marker with which ovarian carcinoma can be diagnosed at levels of sensitivity and specificity which compare favorably to those measured with CA- 125.展开更多
文摘BACKGROUND Early diagnosis of colorectal cancer(CRC)is of great significance to improve the survival rate and quality of life of patients,but early diagnosis of CRC requires more sensitive techniques.Peripheral blood UL16-binding protein 2(ULBP2)and human fibrinogen degradation products(DR-70)are the main indicators for the diagnosis of malignant tumors.AIM To assess ULBP2 and DR-70 potential for the early diagnosis and prognostic evaluation of CRC to provide a reference.METHODS This study involved 60 patients with early-stage CRC(CRC group),50 patients with benign colorectal tumors(benign group),and 50 healthy patients(control group)enrolled at the Affiliated Hospital of Jiangnan University and Jiangsu Province Official Hospital between January,2020 and January,2022.ULBP2 and DR-70 levels in the blood were determined and differences among the three groups and early diagnostic values for CRC were determined.Patients with CRC were divided into the good prognosis and poor prognosis groups,and ULBP2 and DR-70 levels in the blood and diagnostic values were compared.RESULTS ULBP2 and DR-70 serum levels were significantly higher in the CRC group than in the control and benign groups(P<0.05);however,no significant differences were observed between the benign and control groups(P>0.05).Among the 60 patients with CRC followed up for two years,two died(3.33%)and 15 exhibited tumor metastasis,progression,or recurrence(25.00%).ULBP2 and DR-70 serum levels were significantly higher in the poor prognosis group than in the good prognosis group(P<0.05).A receiver operating characteristic curve was plotted.Area under the curve,sensitivity,and specificity of serum ULBP2 with DR-70 for the early diagnosis of CRC were higher than those of the single serum indices(P<0.05)in both the good and poor prognosis groups.CONCLUSION ULBP2 and DR-70 serum levels were significantly high in patients with early-stage CRC.They improved the diagnostic rate of early-stage CRC and predicted patient prognosis,thereby showing clinical application potential.
文摘Background and question: Malignant cells characteristically possess high levels of proteases (e.g. plasminogen activator, cathepsin etc.), which should induce fibrinolysis. The DR- 70(tm) immunoassay quantifies the amount of fibrin degradation products (FDP) in the body. This test system has successfully been used for the detection of a number of cancers including lung, stomach, breast, rectum, liver, colon and uterus cancer. In this paper we tested the diagnostic validity of DR- 70(tm) relative to CA- 125 as a tumor marker for the detection of ovarian carcinoma. Methods: We have simultaneously investigated the serum activities of DR- 70(tm)and CA- 125 from 61 preoperative patients with histologically confirmed ovarian carcinoma. One hundred healthy blood donors served as control group. We measured the FDP utilizing the DR- 70(tm) ELISA as per test instructions of its manufacturer AMDL (Tustin, CA, USA). Results: Low levels of FDP measured by DR- 70(tm) have been detected in the serum of 100 apparently healthy persons (mean ± S.D., 0.41 ± 0.19 μ g/ml). Among the 61 ovarian carcinoma patients, DR- 70(tm) mean value (± S.D.) was 7.0 ± 10.5 μ g/ml in a range of 0.6 to 58.5 μ g/ml. The cut- off level for DR- 70(tm) was set at > 1.2 μ g/ml. The specificity was 100% , whereas the sensitivity was at 83.6% . Relative to CA- 125 a cut- off level of > 65 U/ml was applied. The comparable sensitivity of DR- 70(tm) was higher by 13.1 % . Conclusions: Malignant cells with high levels of proteases are significant contributors to fibrinolysis. The DR- 70(tm) immunoassay has been designed to measure the level of FDP in the serum. DR- 70(tm) represents a tumor marker with which ovarian carcinoma can be diagnosed at levels of sensitivity and specificity which compare favorably to those measured with CA- 125.
